Match tier
Confirmed
Presence
Current · Arkansas
Last published
2023
Sources
OpenAlex · ORCID
Refreshed
2026-10-08
P
Paul L. Prather
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Federal Grant PI
Principal Investigator
Also affiliated: Texas A&M Health Science Center (2012); Atrium Health Wake Forest Baptist (2000); Arkansas Children's Hospital (2012); University of Minnesota (1994–2000); University of Helsinki (2009); University of California, Los Angeles (1995); University of North Texas Health Science Center (1995); George Washington University (2000); Washington University in St. Louis (2009); Cornell University (2000); University of Michigan (2012); University of Arkansas Medical Center (2010–2021); Cayman Chemical (United States) (2012); Michigan Medicine (2012); Arkansas State Crime Laboratory (2012); Arkansas Department of Health (2009–2012); Wake Forest University (2000); Texas A&M University (2012)
39 h-index
121 pubs
4,760 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Paul L. Prather's research focuses on the pharmacology of cannabinoids and their receptors, particularly the CB1 and CB2 receptors. His work investigates the synthesis, molecular pharmacology, and structure-activity relationships of novel cannabinoid receptor antagonists, with an emphasis on developing selective compounds. Prather's publications also explore the metabolism of synthetic cannabinoids and their pharmacodynamic properties, including their affinity and efficacy at CB1 receptors, as well as atypical signaling properties.
His research extends to the potential therapeutic applications of targeting cannabinoid receptors, including in cancer. Studies have characterized cannabinoid receptor expression in various cancer cell types, such as Ewing sarcoma, as potential targets for anti-cancer drug development. Furthermore, his work examines non-canonical cannabinoid receptors that mediate cell death in cancer cells. Prather has received federal funding from the NIH/National Institute of General Medical Sciences for the Systems Pharmacology and Toxicology Training Program, totaling $168,193. He has an h-index of 39 with over 4,700 citations across 122 publications, and collaborates with researchers at the University of Arkansas for Medical Sciences, including Lisa K. Brents, Kyounghyun Kim, William E. Fantegrossi, and Amal Shoeib.
Metrics
- h-index: 39
- Publications: 121
- Citations: 4,760
Positions
-
Principal Investigator 1995–presentUniversity of Arkansas for Medical Sciences Pharmacology and Toxicology ORCID
Selected Publications
-
Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats (2023)
-
Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats (2022)
-
Similar 5F-APINACA Metabolism between CD-1 Mouse and Human Liver Microsomes Involves Different P450 Cytochromes (2022)
-
Non-Canonical Cannabinoid Receptors with Distinct Binding and Signaling Properties in Prostate and Other Cancer Cell Types Mediate Cell Death (2022)
-
Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors (2022)
-
Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development (2021)
-
Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors (2021)
-
Major Metabolites of the Synthetic Cannabinoid 5F‐ADB Retain High Affinity and Full Efficacy at CB1 Receptors; Potential Mechanism Contributing to Enhanced Toxicity? (2021)
-
Synthesis, Molecular Pharmacology, and Structure–Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists (2021)
-
Significance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics (2020)
-
Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands (2020)
-
7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands (2020)
-
Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity (2020)
-
Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N‐(adamantan‐1‐yl)‐1‐(5‐fluoropentyl)‐1H‐indole‐3‐carboxamide (STS‐135) (2020)
-
Oxidative Metabolism and Comparative Analysis of Synthetic Cannabinoid N‐(1‐adamantyl)‐1‐(5‐fluoropentyl)indazole‐3‐carboxamide (5F‐AKB‐48) and the Unfluorinated Analog AKB‐48 (2019)
Federal Grants 1 $168,193 total
NIH
Contact PI
Jul 2013 - Jun 2023
Collaboration Network
Top Collaborators
William E. Fantegrossi
University of Arkansas for Medical Sciences
28 shared publications
In database
- Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: Mechanism underlying greater toxicity?
- Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity
- Quantitative Measurement of JWH-018 and JWH-073 Metabolites Excreted in Human Urine
- Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity
- Forensic investigation of K2, Spice, and “bath salt” commercial preparations: A three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds
Showing 5 of 28 shared publications
Anna Radomińska‐Pandya
University of Arkansas for Medical Sciences
24 shared publications
In database
- Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: Mechanism underlying greater toxicity?
- Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands
- Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic Cannabinoids
- Quantitative Measurement of JWH-018 and JWH-073 Metabolites Excreted in Human Urine
- Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity
Showing 5 of 24 shared publications
Lisa K. Brents
University of Arkansas for Medical Sciences
18 shared publications
In database
- Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity
- Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands
- Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity
- The K2/Spice Phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products
- AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies
Showing 5 of 18 shared publications
Benjamin M. Ford
University of Arkansas for Medical Sciences (US)
16 shared publications
- Synthetic Pot: Not Your Grandfather’s Marijuana
- Characterization of structurally novel G protein biased CB 1 agonists: Implications for drug development
- Design, Synthesis, and Biological Evaluation of Aminoalkylindole Derivatives as Cannabinoid Receptor Ligands with Potential for Treatment of Alcohol Abuse
- Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity
- CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen
Showing 5 of 16 shared publications
Jeffery H. Moran
University of Arkansas for Medical Sciences
16 shared publications
In database
- Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: Mechanism underlying greater toxicity?
- Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity
- Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands
- Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic Cannabinoids
- Quantitative Measurement of JWH-018 and JWH-073 Metabolites Excreted in Human Urine
Showing 5 of 16 shared publications
Lirit N. Franks
University of Arkansas for Medical Sciences
15 shared publications
In database
- AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies
- Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors
- Repeated administration of phytocannabinoid Δ9-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner
- Characterization of structurally novel G protein biased CB 1 agonists: Implications for drug development
- Design, Synthesis, and Biological Evaluation of Aminoalkylindole Derivatives as Cannabinoid Receptor Ligands with Potential for Treatment of Alcohol Abuse
Showing 5 of 15 shared publications
Peter A. Crooks
University of Arkansas for Medical Sciences
13 shared publications
In database
- Characterization of structurally novel G protein biased CB 1 agonists: Implications for drug development
- Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands
- Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors
- Antinociceptive effects of the 6- O -sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors
- Evaluation of Analgesia, Tolerance, and the Mechanism of Action of Morphine-6-O-Sulfate Across Multiple Pain Modalities in Sprague-Dawley Rats
Showing 5 of 13 shared publications
Kathryn A. Seely
University of Arkansas for Medical Sciences (US)
12 shared publications
- The CB2 cannabinoid agonist AM‐1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset
- Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands
- Marijuana-based Drugs: Innovative Therapeutics or Designer Drugs of Abuse?
- Forensic investigation of K2, Spice, and “bath salt” commercial preparations: A three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds
- AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies
Showing 5 of 12 shared publications
Azure L. Yarbrough
University of Arkansas for Medical Sciences
10 shared publications
In database
- Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants
- Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Δ9-THC
- Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity
- Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N‐(adamantan‐1‐yl)‐1‐(5‐fluoropentyl)‐1H‐indole‐3‐carboxamide (STS‐135)
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
Showing 5 of 10 shared publications
Laura P. James
University of Arkansas for Medical Sciences
7 shared publications
In database
- Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands
- Quantitative Measurement of JWH-018 and JWH-073 Metabolites Excreted in Human Urine
- Marijuana-based Drugs: Innovative Therapeutics or Designer Drugs of Abuse?
- Forensic investigation of K2, Spice, and “bath salt” commercial preparations: A three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds
- Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants
Showing 5 of 7 shared publications
Narsimha Reddy Penthala
University of Arkansas for Medical Sciences
7 shared publications
In database
- Characterization of structurally novel G protein biased CB 1 agonists: Implications for drug development
- Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands
- Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors
- Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs
- Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein–Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with Δ9-Tetrahydrocannabinol and JWH-018
Showing 5 of 7 shared publications
Christian V. Cabanlong
University of Arkansas for Medical Sciences (US)
7 shared publications
- Characterization of structurally novel G protein biased CB 1 agonists: Implications for drug development
- Synthesis, Molecular Pharmacology, and Structure–Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists
- Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity
- Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors
- Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein–Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with Δ9-Tetrahydrocannabinol and JWH-018
Showing 5 of 7 shared publications
Ryoichi Fujiwara
University of Arkansas for Medical Sciences (US)
7 shared publications
- Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants
- Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Δ9-THC
- Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity
- Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N‐(adamantan‐1‐yl)‐1‐(5‐fluoropentyl)‐1H‐indole‐3‐carboxamide (STS‐135)
- Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22)
Showing 5 of 7 shared publications
Amal Shoeib
University of Arkansas for Medical Sciences
7 shared publications
In database
- Synthesis, Molecular Pharmacology, and Structure–Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists
- Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity
- 7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
- Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22)
Showing 5 of 7 shared publications
Maheswari Rajasekaran
University of Arkansas for Medical Sciences (US)
5 shared publications
- AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies
- Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors
- Non-Selective Cannabinoid Receptor Antagonists, Hinokiresinols Reduce Infiltration of Microglia/Macrophages into Ischemic Brain Lesions in Rat via Modulating 2-Arachidonolyglycerol-Induced Migration and Mitochondrial Activity
- Gambogic acid binds to human CB2 receptors and exhibits potential partial agonist activity
- The omega and omega‐1 monohydroxyl metabolites of the abused K2/Spice synthetic cannabinoids JWH‐018 and JWH‐ 073 bind with high affinity and act as agonists at human cannabinoid 2 receptors (hCB2s)
Similar Researchers
Based on overlapping research topics
Azure L. Yarbrough
University of Arkansas for Medical Sciences
Cannabis and Cannabinoid Research
Receptor Mechanisms and Signaling
Pharmacological Effects and Toxicity Studies
J S James
University of Arkansas for Medical Sciences
Cannabis and Cannabinoid Research
Receptor Mechanisms and Signaling
Pharmacological Effects and Toxicity Studies
Amal M. Shoeib
University of Arkansas for Medical Sciences
Cannabis and Cannabinoid Research
Receptor Mechanisms and Signaling
Pharmacological Effects and Toxicity Studies
Lirit N. Franks
University of Arkansas for Medical Sciences
Cannabis and Cannabinoid Research
Receptor Mechanisms and Signaling
Pharmacological Effects and Toxicity Studies
Lisa K. Brents
University of Arkansas for Medical Sciences
Cannabis and Cannabinoid Research
Receptor Mechanisms and Signaling
Pharmacological Effects and Toxicity Studies
Pritam Saha Podder
University of Arkansas for Medical Sciences
Receptor Mechanisms and Signaling
Pharmacological Effects and Toxicity Studies
Cancer Treatment and Pharmacology